Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea

Detalles Bibliográficos
Autores principales: Renso, Rossella, Aroldi, Andrea, Pioltelli, Pietro, Gambacorti-Passerini, Carlo, Elli, Elena Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995877/
https://www.ncbi.nlm.nih.gov/pubmed/29891835
http://dx.doi.org/10.1038/s41408-018-0091-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995877/
https://www.ncbi.nlm.nih.gov/pubmed/29891835
http://dx.doi.org/10.1038/s41408-018-0091-6

Ejemplares similares